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Gap junctions are present in the juxtaglomerular apparatus
enabling intercellular communication. Our study determined
the location of different connexin subtypes within the
juxtaglomerular apparatus of the rat, and the role of these
subtypes in renal hemodynamics through the use of specific
mimetic peptides. Immunohistochemical analysis showed
connexins 37 and 40 expression in the endothelial and
renin-secreting cells of the afferent arteriole, while connexin
40 was also found in extra- and intraglomerular mesangial
cells. In contrast, connexin 43 was weakly expressed in
endothelial cells of the afferent arteriole and within the
glomerulus. Intra-renal infusion of the peptides (GAP)
reported to block specific gap junctions (Cx37,43GAP27 or
Cx40GAP27), elevated blood pressure, plasma renin activity,
and angiotensin II levels, while decreasing renal plasma
flow without a significant change in the glomerular filtration
rate. Subsequent restoration of blood pressure reduced
both renal plasma flow and glomerular filtration rate. In
contrast, Cx43GAP26 reduced glomerular filtration rate
without alterations in blood pressure, renal plasma flow,
plasma renin activity, or angiotensin II levels. Hence,
connexins 37 and 40 are expressed in the rat juxtaglomerular
apparatus and these proteins control, in part, the
renin–angiotensin system and renal autoregulation.
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Gap junctions enable direct intercellular communication
via low molecular weight chemical mediators (o1kDa) or
changes in membrane potential.1 Six connexins (Cx) oligo-
merize to form a connexon or hemichannel in the plasma
membrane. At least 20 Cxs have been cloned and each
connexon may be composed of a single type of Cx (homo-
meric) or of different Cxs (heteromeric). Docking with a
counterpart from an adjacent cell creates a gap junction, which
can be made of identical (homotypic) or different connexons
(heterotypic). The loss of a particular Cx subtype by genetic
mutation could therefore not only change ionic communica-
tion, but also alter the range of molecules exchanged between
two cells if the other Cxs are expressed by the same cells.2
Moreover, data using animals in which a specific Cx has been
deleted suggest that compensatory changes can occur in the
remaining Cxs.3 Nevertheless, there is an emerging concept
that Cxs play an important role in physiological processes
including ovarian follicle formation, spermatogenesis, lens
transparency, cardiac development, and blood pressure
regulation.1–6 Various Cxs are expressed in the cardiovascular
system. In the heart, Cxs40 and 43 have been shown to play
important roles in cardiac development and impulse propaga-
tion,5–7 while in blood vessels, gap junctions within the
endothelium, smooth muscle, and between the two cell layers
have been implicated in a number of vasomotor responses that
may regulate vascular tone and blood pressure.3,8
The juxtaglomerular apparatus is anatomically charac-
terized by the interposition of mesangial cells between
macula densa cells and afferent arteriolar myocytes.9,10
Although there is a wide interstitial space between the
macula densa and the mesangial cells,11 afferent arteriolar
myocytes and endothelial cells are tightly connected with gap
junctions, which enable intercellular communication.9,12 In
the kidneys of rats and mice, Cx40 is highly expressed in the
endothelial and renin-secreting cells of the afferent arterioles
and in the extra- and intraglomerular mesangial cells.7,13–15
Cx37 is also highly expressed in the juxtaglomerular
apparatus of mice, as well as in the smooth muscle cells of
renal arteries and arterioles,14 while Cx43 is only detected
in endothelial cells.14 Importantly, deletion of Cx40 in mice
has been reported to result in hypertension16,17 and recently
these modified mice have been shown to lack the inhibition
of renin secretion by high intravascular pressure.18 However,
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replacement of Cx43 with Cx32 has been reported to reduce
renin expression and prevent the development of reno-
vascular hypertension.19 In contrast, in rats, expression of
Cx37 has been described to be limited to endothelial cells,15
while expression of Cx43 remains controversial.7,15,20,21 These
data suggest that the renal expression of particular Cx
subtypes may vary between rats and mice.
Gap junctions within the juxtaglomerular apparatus may
play an important role in the autoregulation of renal blood
flow, which in turn is mediated by both myogenic response of
preglomerular vessels and tubuloglomerular feedback, which
links constriction of terminal portion of the afferent arteriole
to alterations in salt concentration at the macula densa. Gap
junctions in the juxtaglomerular apparatus may also play
a role in regulation of renin–angiotensin system. In this
study we tested this hypothesis by determining the expression
of Cxs37, 40, and 43 in the juxtaglomerular apparatus, and
by investigating the specific roles of these Cxs in renal
hemodynamics and renin–angiotensin system using subtype-
selective gap junction blockers in rats. As many of the
putative gap junction antagonists have been reported to have
nonspecific effects,22,23 we used the GAP peptides to probe
physiological function. These peptides are reported to block
specific Cxs through mimicry of extracellular sequences.24,25
RESULTS
Immunohistochemistry
Strong staining for Cx37 was found demarking endothelial
cell borders in all arteries (Figure 1a); however, no evidence
was found for any staining in the smooth muscle cells. Stain-
ing was also found among endothelial cells of the afferent
arterioles and this continued up to the point where the
arterioles entered the glomerulus (Figure 1b, c and inset, e).
Renin-secreting cells colocalized with the terminal myosin-
stained cells of the afferent arteriole at the entrance to the
glomerulus (Figure 4d). Punctate staining for Cx37 could be
found clearly associated with these cells (Figures 1e, f, and
4e). Occasionally, weak punctuate staining could be found
between smooth muscle cells at more proximal sites along the
afferent arteriole.
In the glomerulus, staining for Cx37 was confined to the
vascular pole around the entry of the afferent arteriole and
exit of the efferent arteriole (Figure 1b and e). There was no
evidence for any Cx37 expression in extra-glomerular mesan-
gial cells. Punctate staining for Cx37 could be seen weakly in
the endothelial layer of the exiting efferent arterioles (Figure
1b, d and inset). Although this staining increased in intensity
with distance from the glomerulus, it was always less exten-
sive than that in the afferent arterioles (Figure 1b, compare
Figure 1c with d).
Cx40 was strongly expressed in the endothelium of all
arteries (Figure 2a) and this staining continued along the
endothelial cells of the afferent arterioles and into the
glomerulus (Figure 2b). Renin-secreting cells expressed Cx40
strongly (Figures 2b, c and inset,); however, there was no
evidence for expression of Cx40 in smooth muscle cells along
the afferent arteriole, or in the efferent arteriole, or any other
artery.
Cx40 was expressed throughout the glomerulus and extre-
mely strongly in the extra-glomerular mesangium (Figure
2b–d). Cx40 expression within the glomerulus did not colo-
calize with the endothelial marker, von Willebrand factor.
There was no expression of Cx40 in either the endothelium
or smooth muscle of the efferent arterioles (Figure 2d and
inset).
While Cx43 was expressed strongly in the endothelium
of large and small arteries (Figure 3a), it was only weakly
expressed in the endothelium of the afferent arterioles up
to their entry into the glomerulus (Figure 3b, c and inset).
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Figure 1 | Cx37 staining in the renal vasculature. (a) Cx37 (red)
is expressed in the endothelial cells (EC) but not in the smooth
muscle cells (SMC; green, stained with anti-myosin) of renal arteries.
(b) Cx37 is also expressed in the endothelial cells of the afferent
arterioles (aa) and at the vascular pole of the glomerulus (gl). (c) High
power of afferent arteriole in (b) shows Cx37 in endothelium (inset
without myosin staining). (d) High power of efferent arteriole (ea)
in (b) shows weak staining in the endothelium but not in the
smooth muscle (inset without myosin staining). (e) Cx37 is also
expressed in the renin-secreting cells (rsc), which stain for myosin.
(f) Same field as (e) without myosin staining.
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In contrast, Cx43 was not expressed in the endothelium
of the efferent arterioles (Figure 3b, d and inset) and there
was no expression in the smooth muscle of any vessel.
Cx43 was also not expressed in the renin-secreting cells or
extra-glomerular mesangium (Figure 3c and d). Within
the glomerulus, there was sparse punctate staining, which
was abolished by preincubation in the antigenic peptide
(compare Figures 3b and 4c). This Cx43 staining did not
colocalize with Cx40 or with the endothelial marker, von
Willebrand factor.
All staining attributed to the antibodies against Cxs37, 40,
and 43 was abolished by preincubation with the antigenic
peptide or omission of the primary antibody (Figure 4a–c,
Cxs37, 40, and 43, respectively).
Hemodynamics
Intra-renal infusion of Cx40GAP27 and Cx37,43GAP27 resulted
in an elevation of blood pressure (Figure 5a; Cx40GAP27
100±1 to 110±2 mm Hg, Po0.05; Cx37,43GAP27 98±2
to 114±2 mm Hg, Po0.01), while infusion of Cx43GAP26
did not alter blood pressure (Figure 5a). Furthermore, the
magnitude of the increase in blood pressure by Cx37,43GAP27
was greater than that by Cx40GAP27 (Po0.05). Renal plasma
flow (RPF) was decreased by Cx40GAP27 (4.25±0.22 to
3.70±0.24 ml per min per g kidney wt, Po0.05) and by
Cx37,43GAP27 (4.48±0.33 to 3.80±0.26 ml per min per g
kidney wt, Po0.01). Although Cx43GAP26 tended to reduce
RPF, it did not attain significance (Figure 5b). Glomerular
filtration rate (GFR) was not altered by either Cx40GAP27 or
Cx37,43GAP27 (Figure 5c), but was decreased by Cx43GAP26
(1.02±0.03 to 0.92±0.03 ml per min per g kidney wt,
Po0.05). Filtration fraction was raised by infusion of either
Cx40GAP27 (25±2 to 28±2%, Po0.05) or Cx37,43GAP27
(23±2 to 28±2%, Po0.05), but not byCx43GAP26 (Figure 5d).
In rats treated with Cx37,43GAP27, pressure restoration
caused a further reduction in RPF (to 3.39±0.22 ml per min
per g kidney wt, Po0.05) and also reduced GFR (1.05±0.04
to 0.97±0.03 ml per min per g kidney wt, Po0.05).
Returning mean arterial pressure to the basal level in the
presence of Cx40GAP27 also lowered GFR (1.03±0.02 to
0.95±0.02 ml per min per g kidney wt, Po0.05) and RPF (to
3.47±0.22 ml per min per g kidney wt, Po0.05).
Intravenous infusion of angiotensin II (10 ng min1) ele-
vated blood pressure (102±4 to 120±3 mm Hg, Po0.01)
and reduced RPF (4.45±0.52 to 3.50±0.50 ml per min per g
kidney wt, Po0.05) without any change in GFR (1.02±0.03
to 1.00±0.03 ml per min per g kidney wt), effects similar to
those seen for Cx37,43GAP27 and Cx40GAP27. The dose of
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Figure 2 | Cx40 staining in the renal vasculature. (a) Cx40 (red) is
expressed in the endothelial cells (EC) but not in the smooth muscle
cells (SMC; green, stained with anti-myosin) of renal arteries. (b) Cx40
is also expressed in the endothelial cells of the afferent arterioles (aa),
in the extraglomerular mesangial cells (egm), renin-secreting cells
(rsc), and throughout the glomerulus (gl). (c) High power of afferent
arteriole in (b) shows Cx40 in endothelium and in the renin-secreting
cells (inset without myosin staining). (d) High power of efferent
arteriole (ea) in (b) shows staining in the extraglomerular mesangial
cells but not in the endothelium or smooth muscle cells (inset
without myosin staining).
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Figure 3 | Cx43 staining in the renal vasculature. (a) Cx43 (red) is
expressed in the endothelial cells (EC) of peritubular capillaries (ptc)
and renal arteries, but not in the smooth muscle cells (SMC; green,
stained with anti-myosin) of renal arteries. (b) Cx43 is also expressed
weakly in the endothelial cells of the afferent arterioles (aa) and very
sparsely in the glomerulus (gl). (c) High power of afferent arteriole in
(b) shows Cx43 in endothelium (inset without myosin staining).
(d) High power of efferent arteriole (ea) in (b) shows absence of
staining in the endothelium or smooth muscle (inset without
myosin staining).
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angiotensin II was selected to obtain an increase in blood
pressure comparable to GAP peptides. However, pressure
restoration to 101±3 mm Hg induced no further change
in either RPF (to 3.52±0.51 ml per min per g kidney wt)
or GFR (to 0.99±0.02 ml per min per g kidney wt) during
angiotensin II infusion.
Renin–angiotensin
Figure 6a depicts the effects of GAP peptide on plasma renin
activity. Plasma renin activity was elevated by an intra-renal
infusion of either Cx40GAP27 (20±2 ng ml1 h1, n¼ 6,
Po0.05) or Cx37,43GAP27 (24±1 ng ml1 h1, n¼ 6, Po0.01),
compared to the control (10±1 ng ml1 h1). The magnitude
of increments in plasma renin activity tended to be higher in
rats treated with Cx37,43GAP27 than Cx40GAP27 but it did
not attain statistical significance. However, the infusion of
Cx43GAP26 had no effect on plasma renin activity. Similarly,
angiotensin II levels were elevated by an intra-renal infusion
of either Cx40GAP27 (47±2 pg ml1, n¼ 6, Po0.05) or
Cx37,43GAP27 (72±10 pg ml1, n¼ 6, Po0.01), compared
to the control (24±3 pg ml1, n¼ 6; Figure 6b). The degree
of increase in angiotensin II was significantly greater in rats
treated with Cx37,43GAP27 than Cx40GAP27 (Po0.05). In con-
trast, infusion of Cx43GAP26 had no effect on angiotensin II
levels.
DISCUSSION
Our anatomical studies have demonstrated expression of
both Cx37 and Cx40 in the endothelial cells of the afferent
arteriole and the renin-secreting cells of the juxtaglomerular
apparatus, with additional expression of Cx40 in the extra-
and intraglomerular mesangial cells. In contrast, Cx43 was
only detected weakly in the endothelium of the afferent
arteriole, sparsely within the glomerulus, and not at all in the
juxtaglomerular apparatus. Importantly, our functional
studies using specific Cx mimetics have shown that inhibition
of the action of Cxs37 and 40, but not Cx43, in the intact
kidney leads to an increase in plasma renin activity and
angiotensin II levels, a significant increase in blood pressure,
and decrease in RPF. Restoration of blood pressure to
control levels produced further decreases in RPF and GFR,
changes which were not seen following pressure restoration
during infusion of angiotensin II. These data suggest that gap
junctions containing Cxs37 and 40 are integral to the control
of the renin–angiotensin system and to renal autoregulation.
Cx40 was widely distributed in the rat juxtaglomerular
apparatus, including the extra- and intraglomerular mesan-
gium, preglomerular endothelial cells, and renin-secreting
cells, consistent with previous studies in mice and rats.13–15
Our physiological data demonstrating a decrease in RPF and
increase in blood pressure following infusion of Cx40GAP27
concur with those of de Vriese et al.,26 who showed a similar
effect with a bolus intrarenal infusion of Cx40GAP27. In
addition, we found that Cx40GAP27 increased filtration
fraction without any change in GFR, suggesting preferential
postglomerular vasoconstriction. Although de Vriese et al.26
found an inhibitory effect of Cx40GAP27 on endothelium-
derived hyperpolarizing factor in the rat kidney, it is unlikely
that effects on endothelium-derived hyperpolarizing factor
were involved in these changes since Wang and Loutzenhi-
ser27 showed that endothelium-derived hyperpolarizing
factor dilated afferent but not efferent arterioles, and hence
loss of endothelium-derived hyperpolarizing factor would be
expected to lead to preglomerular vasoconstriction. However,
we have shown for the first time that intra-renal infusion of
Cx40GAP27 elevated angiotensin II and inhibited renal
autoregulation following pressure restoration. Although
angiotensin II constricts both afferent and efferent arter-
ioles,28 autoregulatory adjustment of vascular tone is limited
to preglomerular vessels, including the afferent arteriole.29–31
An elevation of angiotensin II coupled with attenuation of
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Figure 4 | Specificity controls for Cx antibodies and location of
renin-secreting cells. (a–c) No staining can be seen in the afferent
or efferent arterioles or in the glomerulus when the primary antibody
is preincubated with the antigenic peptide (a, Cx37; b, Cx40; c,
Cx43). (d) Renin (red) is colocalized with myosin in the renin-secreting
cells (rsc) of the afferent arteriole (aa) at the entrance to the
glomerulus (gl); ea, efferent arteriole. (e) Cx37 staining (red; white
arrowheads) colocalizes with renin (green) in the terminal portion
of the afferent arteriole. (f) Cx40 staining (red) also colocalizes with
renin (green) in the terminal portion of the afferent arteriole.
EC, endothelial cells.
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autoregulatory tone by Cx40GAP27 would produce prefer-
ential postglomerular constriction.
Inhibition of Cx40 increased blood pressure in this study.
Mice deficient in Cx40 showed impaired conduction of
arteriolar vasodilation in skeletal muscle, irregular arteriolar
vasomotion, hypertension, and a high incidence of
cardiac malformation.6,16,17,32 The possibility therefore exists
that Cx40GAP27 spilling over from the kidney might have
inhibited systemic vascular Cx40 and increased blood
pressure. Effects of spillover might also be mediated through
the heart as Cx40 is expressed in the cardiac conducting
system.7 However, we observed regular pulses throughout the
experimental periods, speaking against this possibility. An
angiotensin receptor blocker reduced blood pressure in both
wild-type and Cx40 knockout mice.16 We have not used
angiotensin receptor blockers in this study; however, it seems
likely that activation of the renin–angiotensin system is
responsible for the elevation in blood pressure in this study.
Although Cx43 has been suggested to be involved in blood
pressure regulation in rats and mice,19,26 our data suggest
that in rats, additional effects on blood pressure are due to
Cx37 but not Cx43. We have shown for the first time that
Cx37 is expressed in renin-secreting cells and in the afferent
and efferent arteriolar endothelial cells, while Cx43 is only
weakly expressed in the endothelial cells of the afferent
arterioles. In functional studies, Cx37,43GAP27 increased
angiotensin II levels and decreased RPF without changes
in GFR, suggesting a preferential postglomerular vaso-
constriction. Like Cx40GAP27, Cx37,43GAP27 impaired renal
autoregulation. In contrast to Cx37,43GAP27, Cx43GAP26 had
no effect on either the renin–angiotensin system or renal
autoregulation, leading us to conclude that the results were
due to the involvement of Cx37 and not Cx43. Surprisingly,
mice deficient in Cx37 showed impaired conduction of
arteriolar vasodilation33 and susceptibility to atherogenesis,34
but were normotensive.3 Since Cx37,43GAP27 produced an
increase in blood pressure in the this study and an increase
in angiotensin II, compensatory changes in other Cxs in the
Cx37 knockout mice, as has been described previously,
cannot be ruled out.3
In this study, Cx43 was localized to preglomerular
endothelial cells in the rat renal vasculature similar to
previous data in rats and mice.7,14 However, in contrast to
Barajas et al.20 and Guo et al.,21 we did not find Cx43 expres-
sion in extraglomerular mesangial cells, although Cx43 was
sparsely expressed within the glomerulus. Since this latter
Cx43 expression did not colocalize with Cx40, it is likely to
be confined to podocytes. Intra-renal infusion of Cx43GAP26
decreased GFR without changes in filtration fraction, consis-
tent with an effect of Cx43GAP26 in eliciting preglomerular
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Figure 5 | Connexin inhibition and renal hemodynamics. Effects of GAP peptides on (a) blood pressure, (b) RPF, (c) GFR, and (d) filtration
fraction. * and # indicate significance from the value obtained in control and GAP period. Circles, triangles, and rectangles show the data
using GAP27 for Cx40, GAP27 for Cxs37 and 43, and GAP26 for Cx43, respectively.
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vasoconstriction. Although Cx43GAP26 tended to decrease
RPF, it did not reach statistical significance, suggesting a
limitation of the measurements. Mice in which Cx43 is
deleted die at birth and data on blood pressure in
endothelium-specific Cx43 knockout mice are controversial;
mice being either hypotensive35 or normotensive.36 Mice in
which Cx43 has been replaced with Cx32 showed decreased
expression and secretion of renin, but were normotensive.19
In this study, Cx43GAP26 neither altered blood pressure
nor the renin–angiotensin system. Taken together, it seems
unlikely that acute inhibition of intra-renal Cx43 alters
release of vasoconstrictors or vasodilators. Alternatively, it
remains possible that Cx43GAP26 might alter the ultrafiltra-
tion coefficient due to the blockade of Cx43 on podocytes.
Renin release is controlled by various mechanisms,
including afferent arteriolar pressure, macula densa, calcium,
and sympathetic nerve activity. Paracrine factors such as
angiotensin II, nitric oxide, and prostaglandins are also
involved.37,38 Our data support the notion that Cxs regulate
the renin–angiotensin system and suggest that the blunted cell
communication due to the GAP peptides contributes to the
activation of renin–angiotensin system. An interruption to
conduction of autoregulatory signals, especially tubulo-
glomerular feedback, could stimulate renin release directly
by decreasing cytosolic calcium in renin-secreting cells, or
indirectly by decreasing afferent arteriolar pressure.31 If one
assumes that TGF is confined to the distal afferent arteriole
and the myogenic response to more upstream segments, then,
if autoregulation should become impaired due to failure of
TGF alone but not the myogenic response, then this could be
associated with a drop in local intravascular pressure in this
segment (Figure S1). The present data indicate that both
Cx37 and Cx40 are expressed in afferent arteriolar endothelial
cells. Expression of Cx40 is upregulated in endothelial cells
and renin-secreting cells in kidneys of rats with renovascular
hypertension.7 Inhibition of intercellular communication
between renin-secreting cells and endothelial cells by GAP
peptides may result in an elevation of renin and angiotensin
II, possibly modifying the actions of nitric oxide and
prostanoids. While recent data may suggest that Cx37,43GAP27
and Cx40GAP27 could manifest non-junctional effects, it is
possible that some of these effects of the GAP peptides could
be via Cx hemichannels.8,39 Bao et al.40 demonstrated that Cx
hemichannels are mechanosensitive and Yao et al.41 reported
that mechanical stimuli enhanced ATP release from cultured
juxtaglomerular cells, presumably suppressing renin secre-
tion. Clearly, further experiments are required to assess
how Cxs control renin release precisely. Experiments in which
arterial pressure is controlled independently of the deletion
of specific Cxs would be important.
In summary, our findings provide evidence that inter-
cellular communication through Cx37 and Cx40 in the juxta-
glomerular apparatus transduces signals mediating renal
autoregulation and participates in regulation of the renin–
angiotensin system.
MATERIALS AND METHODS
The anatomical and physiological studies described here were
conducted independently and in a blinded fashion in two separate
locations, Australia and Japan, respectively.
Immunohistochemistry
Male Wistar Kyoto rats aged 8–10 weeks were anesthetized with
ether and decapitated under a protocol approved by the Animal
Experimentation and Ethics Committee of the Australian National
University. Both kidneys were removed and 1–2 mm thick transverse
sections cut and immersion fixed in cold acetone for 20 min at 41C.
Blocks were infiltrated with 30% sucrose in phosphate-buffered
saline, embedded in Cryo-M-Bed (Bright Instrument Company,
Cambridge, UK) and cryosectioned coronally at 30 mm. Sections
were preincubated in 2% bovine serum albumin, 0.2% Triton X-100
in phosphate-buffered saline for 30 min, and incubated for 1 or
2 days at room temperature in the same solution containing
sheep antibodies against Cxs37 and 40,42,43 rabbit antibodies against
Cx43 (1:250; Zymed, San Francisco, CA, USA), or mouse or sheep
antibodies against rat renin (1:500, Swant, Bellinzona, Switzerland;
1:1000, Sapphire Bioscience, Redfern, NSW, Australia respectively).
Staining was detected using Cy3-conjugated anti-goat (1:600) or
anti-rabbit (1:100) immunoglobulins (Jackson Labs, West Grove,
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Pennsylvania, USA) or Alexa Fluor 568 anti-mouse immuno-
globulins (1:800; Molecular Probes, Eugene, Oregon, USA) in
phosphate-buffered saline containing 0.01% Triton X-100. Localiza-
tion of the staining in the arteries and arterioles was confirmed
by subsequent staining with rabbit anti-smooth muscle myosin
(1:250; Goschel Stewart, Darmstadt, Germany) or rabbit antihuman
von Willebrand factor (1:300; Dako, Glostrup, Denmark) for 1 h at
room temperature and detected using fluorescein isothiocyanate-
conjugated anti-rabbit immunoglobulin (1:40; Dako).
Subtype specificity of all three Cx antibodies has been previously
demonstrated using immunohistochemistry and western blotting of
COS cells transfected with plasmid DNA encoding Cxs37, 40, or
43.43 Further tests of specificity involved omission of the primary
antibody or preincubation of the primary antibody with a 10-fold
excess of the immunizing peptide.
Sections were mounted in buffered glycerol and viewed with a
Leica TCS confocal scanning microscope. Series of images of the
juxtaglomerular apparatus were collected every 1 mm and recon-
structed to provide views throughout the vessel and glomerular
depth. Sections of kidneys taken from each of four different rats
were tested with antibodies against all three of the Cxs.
Hemodynamics
Experiments were performed using 8- to 10-week-old male Wistar
Kyoto rats (Shizuoka Laboratory Animal Center, Shizuoka, Japan)
and all experimental protocols were approved by the Ethical
Committee of the Saitama Medical College. Animals were allowed
free access to tap water and standard rat chow (CE-2, Nihon CLEA,
Tokyo, Japan). On the day of experiment, the rats were anesthetized
with pentobarbital sodium (50 mg kg1, intraperitoneally) and
placed on a thermostatically controlled heated table to keep body
temperature at 371C as detailed previously.10,44 A tracheostomy was
performed, and the right jugular vein was cannulated with
polyethylene tubing (PE50) to allow infusion of solutions and
additional anesthetic. The animals were infused at the rate of
1.2 ml h1 with isotonic saline solution containing 6% bovine serum
albumin (Sigma-Aldrich Chemicals, St Louis, MO, USA) during
surgery, and thereafter with isotonic saline solution containing 1%
bovine serum albumin, 7.5% Inutest (Laevosan-Gesellschaft, Linz/
Donau, Austria), and 1.5% para-aminohippuric acid (Merck Sharp
and Dohme, West Point, PA, USA) to enable calculation of GFR and
effective RPF. The left femoral artery was catheterized with PE50
filled with heparinized saline (100 U ml1) to allow blood sampling
and continuous arterial pressure measurements with a transducer
(DX-100, Nihon Kohden Co. Ltd, Tokyo, Japan) and a polygraph
recorder (RM-7000, Nihon Kohden). Mean arterial pressure was
used as renal arterial pressure. There was no irregularity of the
arterial pulse throughout experimental periods. The abdomen was
opened by a midline incision. The left ureter was cannulated (PE10),
and urine was collected under mineral oil in preweighed tubes.
An adjustable clamp was placed on the aorta above the left renal
artery to control left renal arterial pressure. For GAP peptide
experiments, the left adrenal artery was cannulated with extended
PE10 to infuse heparinized saline or GAP peptides (5 mg intra-
arterially followed by 0.2 mg min1) at a rate of 0.6 ml h1,10,26,45
and the solution for transjugular infusion was adjusted to that
containing 2% bovine serum albumin and infused at the rate of
0.6 ml h1 to make water load similar. In the case of Cx40GAP27
saline containing acetic acid was used as a vehicle. Preliminary
studies showed that hemodynamic effects caused by the GAP
peptides were maintained constant for 4 h at the doses used in this
study. Rats were allowed to breathe air enriched with 100% oxygen,
which markedly improves the stability of arterial blood pressure.
After completion of surgery, 1 h of equilibration was allowed before
initiating experimental protocols.
The experiments contained three groups, and were performed on
six rats for each group to characterize systemic and renal
hemodynamic effects of GAP peptides. Initially, saline was infused
into the left renal artery through the adrenal artery. Two consecutive
20-min control clearances were carried out. Then, the infusion of
GAP peptide into the adrenal artery was initiated, and continued
until the end of study. Cx43GAP26 (Severn Biotech, Worcestershire,
UK), Cx40GAP27 (Severn Biotech), and Cx37,43GAP27 (Sigma-Aldrich)
were used for each group.26,46 A 20-min equilibration period was
allowed before initiating two consecutive 20-min clearance periods.
Then, the aortic clamp was tightened to return renal arterial pressure
to the control level if necessary. Another 20-min equilibration period
was allowed before initiating two consecutive 20-min clearance
periods. In preliminary studies, the intra-aortic injection of
Cx40GAP27, Cx43GAP26, and Cx37,43GAP27 (1 mg) induced a prompt
increase, a decrease, and an insignificant change in blood pressure,
respectively. Intra-renal infusion of Cx40GAP27 and Cx37,43GAP27
resulted in an elevation of blood pressure. That of Cx43GAP26 did not
alter blood pressure. These discrepancies suggest that the amount of
GAP peptide spilled over from the kidney was not large enough to
affect the systemic circulation. In a fourth group of rats (n¼ 5), the
effects of intravenous infusion of angiotensin II (10 ng min1) on
renal hemodynamics were assessed in a similar manner, and served
as the time control. This dose of angiotensin II infusion would induce
about three-fold increases in plasma angiotensin II.47 Previous
study indicated that renal angiotensin II levels were much higher
than plasma levels in rats.44
Arterial blood samples (approximately 0.2 ml) were taken at the
midpoint of each clearance period. Cells were separated by centri-
fugation and plasma was removed. Urine volume was determined
gravimetrically. Inulin and para-aminohippuric acid concentrations
in both plasma and urine were measured by standard spectro-
photometry. At the end of the experiment, the rats were killed with
an overdose of pentobarbital, and the left kidney was removed,
decapsulated, blotted dry, and weighed.
Renin–angiotensin
In additional experiments, angiotensin II levels were determined in
four groups of rats using RIA, as described previously.10,44 Surgical
procedures were the same as the above, except that the ureter was not
cannulated. After 1 h of equilibration, the three GAP peptides were
infused separately into the adrenal artery in three groups of rats. The
remaining group served as the control in which saline was infused
into the adrenal artery. Twenty minutes later, 2 ml of blood sample
was taken from the femoral artery in chilled tubes containing EDTA.
In a similar manner, plasma renin activity was measured separately in
four groups of rats with RIA (Renin RIA Kit, Yamasa Soysauce Co.
Ltd, Chiba, Japan). Blood samples were centrifuged at 41C for
10 min. Plasma was kept frozen until assayed. We confirmed that
each of three types of GAP peptides did not interact against the assay.
Statistics
Data were expressed as means±s.e.m. Statistical analysis was
performed, using analysis of variance for repeated measurements
and Student’s t-test with or without Bonferroni correction for
multiple comparisons when appropriate. Po0.05 was considered as
statistically significant.
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